Supplementary Figure S12 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

Pharmacodynamics of STAT3 ASO in CT26 STK11 KO model. (A) Percentage of CD45+ immune cells among live cells from untreated or drug-treated STK11 KO CT26 tumors as indicated. (B) Percentage of Ly6G+ granulocytic cells among live CD45+ cells. (C) Percentage of intratumoral CD103+ cDC1 dendritic cells among CD45+ immune cells. (D) CD86 MFI of CD103+ cDC1s. (E) Percentage of migratory DC among CD45+ cells in TDLN of tumor engrafted mice. (F) CD86 MFI of these migratory DC in TDLNs. (G) Flow cytometry plots of CD86 levels on TDLN migratory DC. (H) Percentage of CD64+ CD11b+ myeloid cells among live intratumoral CD45+ cells. (I) Flow cytometry plots of CD86 on these CD64+ CD11b+ myeloid cells. (J) Percentages of MHCII+ CD206+ intratumoral myeloid cells. (K) Percentage of MHCII+ CD163+ intratumoral myeloid cells.